FDA Approved: COLUMVI — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Columvi (glofitamab) submitted by Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Columvi (glofitamab)

Snippet

SUPPL AP for COLUMVI (GLOFITAMAB)